How Janssen Neuroscience is Addressing the Unmet Needs of Rare Disease Patients
Hong Sun, M.D., Ph.D. is a Senior Director, Global Compound Development Team Leader for the Neuroscience Therapeutic Area at Janssen Research & Development, LLC. In this segment, she discusses how Janssen is working to address the unmet needs of patients impacted by rare diseases, including rare neuromuscular conditions like myasthenia gravis (MG), through the Company’s autoantibody research. Janssen is currently investigating nipocalimab, which uses a unique mechanism of action to accelerate the removal of pathogenic autoantibody in patients affected by MG.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Alzheimer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Alzheimer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Alzheimer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Hong Sun, M.D., Ph.D., is the Global Development Lead for Nipocalimab. Hong is a neurologist by training and also has a Ph.D. in Neuroscience. As a strategic and passionate leader, she is devoted to the development of novel treatments to transform patient life suffering from neurological and psychiatric disorders. With over 15 years of pharmaceutical and biotech experience, Hong has broad development experience ranging from early, late phase clinical development and strategic team leadership with small molecules, biologics and drug-device combinations, in disease areas of Alzheimer’s Disease, sleep disorders, migraine, schizophrenia, myasthenia gravis, and other autoimmune diseases. She has also been a key contributor to the new drug application and approval for two first in class treatments: Belsomria (an orexin antagonist for insomnia), and Aimovig (a CGRP mAb for migraine).
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
